drugset / Trial / NCT01175512

Stress, Hormones, and Eating

NCT01175512

Phase 0 Completed 42 enrolled University of California, San Francisco
Non-randomizedCrossoverTriple-blindOther

Summary

The investigators will develop a measure of endogenous opioid tone that might serve as a biological marker for drive for palatable food. Using a 'naltrexone probe,' the investigators will assess whether individual response to one dose of an opioid receptor antagonist, naltrexone, is related to non-homeostatic eating in non-pregnant women. Hypothesis 1: Naltrexone Response will be related to non-homeostatic eating. Hypothesis 2: Response profiles to the 25 mg dose will be slightly less in magnitude than the 50 mg dose. However, responses will be similarly related to non-homeostatic eating measures. Hypothesis 3: Response to naltrexone will be highly stable within individuals across time, in the absence of an intervention.

Timeline

Start
2010-07
Primary completion
2011-12
Completion
2011-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Naltrexone Small molecule 25 mg
Comparator Naltrexone Small molecule 50 mg

Indications